RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C

被引：0
|
作者：
Turnes, Juan [1 ]
Garcia-Herola, Antonio [2 ]
Morillo, Ramon [3 ]
Mendez, Marinela [4 ]
Rueda, Magdalena [4 ]
Hernandez, Candido [5 ]
Sicras-Mainar, Antoni [6 ]
机构：
[1] CHU, Gastroenterol & Hepatol Dept, Pontevedra, Spain
[2] Hosp Marina Baixa de Villajoyosa, Digest Med Dept, Alicante, Spain
[3] AGS Sur Sevilla, Hosp Valme, Hosp Pharm, Seville, Spain
[4] Gilead Sci SL, Med Affairs, Madrid, Spain
[5] Gilead Sci Europe Ltd, Global Med Affairs, London, England
[6] Atrys Hlth, Hlth Econ & Outcomes Res, Barcelona, Spain
来源：
GUT | 2022年 / 71卷
关键词：
D O I：
10.1136/gutjnl-2022-IDDF.125
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
IDDF2022-A
引用
收藏
页码：A97 / A98
页数：2
相关论文
共 50 条
  • [21] Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain
    Sicras Mainar, Antoni
    Navarro Artieda, Ruth
    Hernandez, Ignacio
    Morillo, Ramon
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2019, 42 (08): : 465 - 475
  • [22] Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
    Ioanna Aggeletopoulou
    Christos Konstantakis
    Spilios Manolakopoulos
    Christos Triantos
    World Journal of Gastroenterology, 2017, (24) : 4317 - 4323
  • [23] Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
    Kao-Chi Chang
    Shui-Yi Tung
    Kuo-Liang Wei
    Chen-Heng Shen
    Yung-Yu Hsieh
    Wei-Ming Chen
    Yi-Hsing Chen
    Chun-Hsien Chen
    Chi-Wei Yen
    Huang-Wei Xu
    Wei-Lin Tung
    Chao-Hung Hung
    Sheng-Nan Lu
    Te-Sheng Chang
    Scientific Reports, 11
  • [24] Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
    Chang, Kao-Chi
    Tung, Shui-Yi
    Wei, Kuo-Liang
    Shen, Chen-Heng
    Hsieh, Yung-Yu
    Chen, Wei-Ming
    Chen, Yi-Hsing
    Chen, Chun-Hsien
    Yen, Chi-Wei
    Xu, Huang-Wei
    Tung, Wei-Lin
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Chang, Te-Sheng
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
    Aggeletopoulou, Ioanna
    Konstantakis, Christos
    Manolakopoulos, Spilios
    Triantos, Christos
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (24) : 4317 - 4323
  • [26] Treatment of hepatitis C in HIV patients in the new era of direct-acting antivirals
    Fernández-Montero J.V.
    Vispo E.
    Barreiro P.
    De Mendoza C.
    Labarga P.
    Soriano V.
    Current Hepatitis Reports, 2013, 12 (4) : 269 - 275
  • [27] New direct-acting antivirals for the treatment of chronic hepatitis C
    Jeong, Sook-Hyang
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (12): : 1154 - 1158
  • [28] Benefits of Direct-Acting Antivirals for Hepatitis C
    Lok, Anna S.
    Chung, Raymond T.
    Vargas, Hugo E.
    Kim, Arthur Y.
    Naggie, Susanna
    Powderly, William G.
    ANNALS OF INTERNAL MEDICINE, 2017, 167 (11) : 812 - +
  • [29] Drug-Drug Interactions in the Era of Direct-Acting Antivirals and Clinical Outcome of Patients with Chronic Hepatitis C.
    Nogueira, Marcel
    Lino, Ana
    Otuyama, Leonardo
    Lucena, Nayara
    Ribeiro Dos Santos, Graziella D'Agostino
    Ambrosio, Veridiana
    Rocha, Priscilla Alves
    Tolentino, Raphael
    Martins, Maria Cleusa
    Pinto, Vanusa Barbosa
    Carrilho, Flair Jose
    Ono, Suzane Kioko
    HEPATOLOGY, 2018, 68 : 398A - 398A
  • [30] Targeting Hepatitis C With Direct-Acting Antivirals
    Pennell, Laurie
    LaPreze, Jennifer
    US PHARMACIST, 2023, 48 (03) : 22 - 27
12345